Catalog No.S1465 Synonyms: BAY12-8039 HCl
Molecular Weight(MW): 437.89
Moxifloxacin is a fourth-generation synthetic fluoroquinolone antibacterial agent.
Purity & Quality Control
Choose Selective Topoisomerase Inhibitors
|Description||Moxifloxacin is a fourth-generation synthetic fluoroquinolone antibacterial agent.|
Moxiﬂoxacin exerts its effects by trapping a DNA drug enzyme complex and speciﬁcally inhibiting ATP-dependent enzymes topoisomerase II (DNA gyrase) and topoisomerase IV. Moxiﬂoxacin shows in-vitro potency against M. tuberculosis H37Rv with MIC of 0.177 μg/mL. Moxiﬂoxacin has broad Grampositive and Gram-negative activity. Moxiﬂoxacin shows in vitro and clinical efﬁcacy against Staphylococcus aureus, Streptococcus pneumoniae, Str. pyogenes, Haemophilus inﬂuenzae, H. parainﬂuenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydia pneumoniae and Mycoplasma pneumoniae. Moxiﬂoxacin has activity against mycobacteria in addition to M. tuberculosis; Moxiﬂoxacin is more active against M. kansasii than M. avium complex: speciﬁcally MIC90 for M. avium > M. intracellulare > M. kansasii at 4, 2 and 2 μg/mL, respectively. MIC90 for M. chelonae > M. fortuitum at 16 and 0.5 μg/mL, respectively. 
|In vivo||Moxiﬂoxacin combined with RIF/pyrazinamide (PZA) reduces treatment time by up to 2 months compared to regimens with isoniazid (INH)/RIF/PZA in a mouse model designed to mimic human disease. Similar results with a stable cure are reached after 4 months in mice treated twice weekly with RIF/Moxiﬂoxacin/PZA compared to cure in 6 months when daily treated with RIF/INH/PZA. 100 mg/kg Moxiﬂoxacin in mice gives activity comparable to INH; increased dose in mice to 400 mg/kg Moxiﬂoxacin daily results in spleen CFU counts lower than for INH 25 mg/kg although the differences are not statistically signiﬁcant. AUC/MIC ratio correlates best with in-vivo efﬁcacy for the ﬂuoroquinolones in a mouse model of tuberculosis. |
|In vitro||DMSO||87 mg/mL (198.68 mM)|
|In vivo||Add solvents individually and in order:
30% PEG400+0.5% Tween80+5% propylene glycol
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).
Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )
* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).
Molecular Weight Calculator
Enter the chemical formula of a compound to calculate its molar mass and elemental composition:
Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2
Instructions to calculate molar mass (molecular weight) of a chemical compound:
To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.
Clinical Trial Information
|NCT Number||Recruitment||Conditions||Sponsor/Collaborators||Start Date||Phases|
|NCT00816426||Completed||Tuberculosis||National Institute of Allergy and Infectious Diseases (NIAID)|Korean Center for Disease Control and Prevention|International Tuberculosis Research Center|Novartis Institute for Tropical Medicine|Asian Medical Center|National Institutes of Health Clinical Center (CC)||December 29, 2008||Phase 1|
|NCT03021616||Not yet recruiting||Cardiovascular Diseases||David Grant U.S. Air Force Medical Center||January 2017||--|
|NCT02589782||Recruiting||Tuberculosis, Multidrug-Resistant|Extensively Drug-Resistant Tuberculosis|Tuberculosis, Pulmonary||Medecins Sans Frontieres, Netherlands|London School of Hygiene and Tropical Medicine|Global Alliance for TB Drug Development|University College, London|Drugs for Neglected Diseases|Swiss Tropical & Public Health Institute|eResearch Technology, Inc.|Ministry of Health, Republic of Uzbekistan|World Health Organization|Ministry of Health, Belarus|TB & HIV Investigative Network (THINK)||January 2017||Phase 2|Phase 3|
|NCT02680080||Not yet recruiting||Long QT Syndrome||Tel-Aviv Sourasky Medical Center|Tel Aviv Medical Center||December 2016||--|
|NCT02754765||Recruiting||Tuberculosis, Multidrug-Resistant||Médecins Sans Frontières France|Partners in Health|Harvard Medical School|Epicentre|Institute of Tropical Medicine, Belgium|Ministry of Health, Kyrgyzstan|National Center for Tuberculosis Problems, Kazakhstan|Ministry of Health, Lesotho|National Center for Tuberculosis and Lung Diseases, Georgia|Socios En Salud, Peru||December 2016||Phase 3|
|NCT02903836||Recruiting||Community-Acquired Bacterial Pneumonia (CABP)||Wockhardt|ACM||September 2016||Phase 2|
Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.